Drug intelligence / Profile preview

EBT-407

Development stage: Preclinical
Lead developer: Ernest Pharmaceuticals
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous

Overview

EBT-407 is a preclinical-stage therapeutic candidate developed by Ernest Pharmaceuticals for the treatment of solid tumors. It utilizes the company's proprietary BacID (Bacterial Intracellular Delivery) platform, which employs engineered, non-pathogenic bacteria to selectively colonize the hypoxic and immunosuppressive environment of solid tumors. Once localized within the tumor, the bacterial vector delivers an oncolytic virus payload. This approach is designed to overcome the delivery challenges of traditional viral therapies by using the bacteria's natural tumor-homing capabilities to transport the virus directly to the cancer cells. The oncolytic virus then replicates within and lyses the tumor cells, while also stimulating a localized anti-tumor immune response.

Beyond the preview

Go deeper on EBT-407.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBT-407.

Explore the full profile